Navigation Links
Longs Drug Stores Corporation Reports Second Quarter Results
Date:8/20/2008

WALNUT CREEK, Calif., Aug. 20 /PRNewswire-FirstCall/ -- Longs Drug Stores Corporation (NYSE: LDG) today reported preliminary income from continuing operations for the second quarter ended July 31, 2008 of $27.5 million, or $0.76 per diluted share, including $0.7 million of after-tax charges, or $0.02 per diluted share, related to provisions for store closures and asset impairments and legal reserves, a 6.8 percent increase compared with income from continuing operations for the second quarter ended July 26, 2007 of $25.7 million, or $0.67 per diluted share.

Second Quarter

Income

Income from continuing operations for the second quarter ended July 31, 2008 was $27.5 million, or $0.76 per diluted share, a 6.8 percent increase compared with income from continuing operations for the second quarter ended July 26, 2007 of $25.7 million, or $0.67 per diluted share. Results for the quarter ended July 31, 2008 included $0.7 million of after-tax charges, or $0.02 per diluted share, related to provisions for store closures and asset impairments and legal reserves.

Revenues

Total revenues of $1.33 billion for the thirteen weeks ended July 31, 2008 were 4.6 percent higher than the $1.27 billion reported for the thirteen weeks ended July 26, 2007.

Retail drug store sales increased 0.5 percent to $1.20 billion for the thirteen weeks ended July 31, 2008. Same-store sales decreased 1.1 percent with pharmacy same-store sales decreasing 0.6 percent and front-end same-store sales decreasing 1.6 percent. Pharmacy sales were 51.6 percent of retail drug store sales during the period, compared with 51.3 percent a year ago.

Pharmacy benefit services revenues increased 66.3 percent to $131.3 million from $79.0 millions

Stockholders' Equity:

Common stock: par value $0.50 per

share, 120,000,000 shares authorized,

35,908,000, 36,204,000 and 37,760,000

shares outstanding 17,954 18,102 18,880

Additional capital 303,982 288,385 283,448

Retained earnings 531,552 521,438 549,482

Total stockholders' equity 853,488 827,925 851,810

Total $1,912,705 $1,846,716 $1,737,615

Condensed Statements of Consolidated Cash Flows (unaudited)

For the 26 weeks ended

July 31, July 26,

2008 2007

Thousands

Operating Activities:

Net income $51,036 $39,645

Adjustments to reconcile net income to

net cash provided by operating activities:

Depreciation and amortization 51,436 46,543

Provision for store closures

and asset impairments, net (21) 5,772

Deferred income taxes and other (2,543) (3,968)

Stock awards and options, net 8,793 14,162

Excess tax benefits related to

stock awards and options (1,030) (6,570)

Common stock contribution to

benefit plan 13,784 10,224

Changes in assets and liabilities:

Accounts receivable (68,484) (12,492)

Merchandise inventories 45,777 (5,403)

Other assets (1,674) (2,082)

Current liabilities and other 23,298 (8,044)

Net cash provided by

operating activities 120,372 77,787

Investing Activities:

Capital expenditures (61,332) (67,059)

Acquisitions (4,931) (12,021)

Proceeds from dispositions of property

and intangible assets 941 19,848

Net cash used in investing activities (65,322) (59,232)

Financing Activities:

Proceeds from revolving line

of credit borrowings, net 25,000 8,000

Repayments of private placement notes (2,728) (2,727)

Repurchase of common stock (39,260) (29,994)

Proceeds from exercise of stock options 3,580 13,356

Dividend payments (10,127) (10,614)

Medicare Part D subsidy receipts

(disbursements), net (30,372) (5,937)

Excess tax benefits related to stock

awards and options 1,030 6,570

Other (2,325) (342)

Net cash used in financing activities (55,202) (21,688)

Decrease in cash and cash equivalents (152) (3,133)

Cash and cash equivalents at

beginning of period 27,019 27,596

Cash and cash equivalents at end of period 26,867 24,463

Supplemental disclosure of cash flow information:

Cash paid for interest, net of

amounts capitalized $5,348 $3,476

Cash paid for income taxes 44,663 16,402

Condensed Statements of Consolidated Stockholders' Equity

Thousands except per share amounts

Total

Common Stock Stock-

Additional Retained holders'

Shares Amount Capital Earnings Equity

Balance at January 25, 2007 37,406 18,703 250,113 546,741 815,557

Cumulative effect of

accounting change (Note 2) (526) (526)

Net income 96,201 96,201

Dividends ($.56 per share) (21,183) (21,183)

Stock contributions to

employee retirement plan 278 139 13,296 13,435

Stock awards, net of

forfeitures 144 72 (5,556) (5,484)

Stock-based compensation

expense 19,926 19,926

Stock options exercised 850 425 19,268 19,693

Tax benefit related to stock

awards and stock options, net 10,094 10,094

Repurchase of common stock (2,474) (1,237) (18,756) (99,795) (119,788)

Balance at January 31, 2008 36,204 $18,102 $288,385 $521,438 $827,925

Net income 51,036 51,036

Dividends ($.28 per share) (10,127) (10,127)

Stock contributions to

employee retirement plan 305 153 13,631 13,784

Stock awards, net of

forfeitures 263 131 (2,374) (2,243)

Stock-based compensation

expense 7,137 7,137

Stock options exercised 137 68 3,512 3,580

Tax benefit related to stock

awards and stock options, net 1,656 1,656

Repurchase of common stock (1,000) (500) (7,965) (30,795) (39,260)

Balance at July 31, 2008 35,909 $17,954 $303,982 $531,552 $853,488

in the comparable period last year. Prescription drug plan revenues were $110.9 million compared with $65.7 million last year and pharmacy benefit management revenues were $20.4 million compared with $13.3 million a year ago.

Retail Drug Store Gross Profit

Retail drug store gross profit for the second quarter ended July 31, 2008 was $320.2 million, or 26.7 percent of retail drug store sales, compared with $314.5 million, or 26.3 percent of retail drug store sales, last year. The increase in gross profit as a percent of sales was primarily due to higher generic utilization and improved inventory management, partially offset by changes in the sales mix reflecting increasing price sensitivity among consumers.

The LIFO charge for the second quarter ended July 31, 2008 was $4.0 million compared with $2.0 million in the second quarter last year.

Prescription Drug Plan Gross Profit

Prescription drug plan gross profit for the second quarter ended July 31, 2008 was $14.4 million, or 13.0 percent of prescription drug plan revenues, compared with $11.5 million, or 17.5 percent of prescription drug plan revenues, last year. As expected, the lower gross profit margin rate on increased revenues reflects the Company's bids submitted for the 2008 plan year.

Operating and Administrative Expenses

Operating and administrative expenses for the second quarter ended July 31, 2008 were $307.4 million, or 23.1 percent of revenues, compared with $295.0 million, or 23.1 percent of revenues, last year. The flat rate compared with last year reflects increased leverage on higher pharmacy benefit services revenues, offset by increased new store activity and reduced leverage on retail drug store sales.

Operating Income

Consolidated operating income for the second quarter ended July 31, 2008 was $46.5 million, or 3.5 percent of revenues. Operating income for the second quarter last year was $44.3 million, or 3.5 percent of revenues.

Retail drug store operating income was $31.6 million, or 2.6 percent of retail drug store sales, compared with $33.4 million, or 2.8 percent of sales last year. Pharmacy benefit services operating income was $14.9 million, or 11.4 percent of pharmacy benefit services revenues, compared with $10.9 million, or 13.8 percent of pharmacy benefit services revenues last year.

First Six Months

Income

Income from continuing operations for the 26 weeks ended July 31, 2008 was $50.6 million, or $1.40 per diluted share, compared with income from continuing operations for the 26 weeks ended July 26, 2007 of $41.8 million, or $1.09 per diluted share, including $5.8 million of after-tax charges related to the disposition of stores.

Revenues

Total revenues of $2.74 billion for the 26 weeks ended July 31, 2008 were 6.5 percent higher than the $2.57 billion reported for the 26 weeks ended July 26, 2007.

Retail drug store sales increased 1.7 percent to $2.42 billion from $2.38 billion in the comparable period last year. Same-store sales decreased 0.1 percent with pharmacy same-store sales flat with last year and front-end same- store sales decreasing 0.1 percent. Pharmacy sales were 52.0 percent of retail drug store sales during the period, compared with 51.8 percent a year ago.

Pharmacy benefit services revenues increased 66.8 percent to $318.6 million from $191.0 million in the comparable period last year. Prescription drug plan revenues were $278.0 million compared with $162.2 million last year and pharmacy benefit management revenues were $40.6 million compared with $28.7 million a year ago.

Retail Drug Store Gross Profit

Retail drug store gross profit for the 26 weeks ended July 31, 2008 was $645.4 million, or 26.7 percent of retail drug store sales, compared with $618.4 million, or 26.0 percent of retail drug store sales, last year. The increase in gross profit as a percent of sales was primarily due to higher generic utilization, increased self-distribution of front-end merchandise and improved inventory management, partially offset by changes in the sales mix reflecting increasing price sensitivity among consumers.

The LIFO charge for the 26 weeks ended July 31, 2008 was $7.5 million compared with $5.0 million a year ago.

Prescription Drug Plan Gross Profit

Prescription drug plan gross profit for the 26 weeks ended July 31, 2008 was $18.4 million, or 6.6 percent of prescription drug plan revenues, compared with $15.6 million, or 9.6 percent of prescription drug plan revenues, last year. As expected, the lower gross profit margin rate on increased revenues reflects the Company's bids submitted for the 2008 plan year.

Operating and Administrative Expenses

Operating and administrative expenses for the 26 weeks ended July 31, 2008 were $617.0 million, or 22.5 percent of revenues, compared with $581.3 million, or 22.6 percent of revenues, last year. The decrease in the expense rate reflects increased leverage on higher pharmacy benefit services revenues, partially offset by increased new store activity and reduced leverage on retail drug store sales.

Operating Income

Consolidated operating income for the 26 weeks ended July 31, 2008 was $86.0 million, or 3.1 percent of revenues. Operating income for the 26 weeks ended July 26, 2007 was $72.3 million, or 2.8 percent of revenues, including a $9.6 million pre-tax charge related to the disposition of stores.

Retail drug store operating income was $66.6 million, or 2.8 percent of retail drug store sales, compared with $56.8 million, or 2.4 percent of sales last year, including the charge related to the disposition of stores. Pharmacy benefit services operating income was $19.4 million, or 6.1 percent of pharmacy benefit services revenues, compared with $15.4 million, or 8.1 percent of pharmacy benefit services revenues last year.

Management Outlook

In light of the Company's announced transaction with CVS Caremark Corporation, the Company will not be including management outlook during the pendency of such transaction.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements relate to, among other things, expected financial results for fiscal year 2009, capital expenditures, progress on strategic initiatives, opening, relocating and remodeling of stores, profits from prescription drug plans, performance of RxAmerica, and are indicated by such words as "will," "expects," "estimates," "goals," "plans" or similar words. These statements are based on the Company's current plans and expectations and involve risks and uncertainties that could cause actual events and results to vary materially from those contemplated by such statements. Risks and uncertainties relate to, among other things, CVS Caremark Corporation's proposed acquisition of the Company, changing market conditions in the overall and regional economy and in the retail industry, the availability and cost of real estate, construction costs and delays, labor unrest, natural or manmade disasters, competition, maintaining satisfactory relationships with vendors, changes in applicable law or in the interpretation of applicable law by regulatory agencies or by legal, accounting or other professional advisors, or by the Company, and other factors described from time to time in the Company's news releases and in its annual, quarterly and other reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended January 31, 2008. Please refer to such filings for a further discussion of these risks and uncertainties. Undue reliance should not be placed on forward-looking statements which speak only as of the date of this news release. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances that may arise after the date of this news release.

About the Company

Headquartered in Walnut Creek, California, Longs Drug Stores Corporation (NYSE: LDG) is one of the most recognized retail drug store chains on the West Coast and in Hawaii. The Company operates 521 retail pharmacies and offers a wide assortment of merchandise focusing on health, wellness, beauty and convenience. Longs also provides pharmacy benefit management services and Medicare beneficiary prescription drug plans through its wholly-owned subsidiary, RxAmerica, LLC. Additional information about Longs and its services is available at http://www.longs.com and more information about RxAmerica is available at http://www.rxamerica.com.

Contact: 925-979-3979

Condensed Consolidated Income Statements (unaudited)

For the 13 weeks ended For the 26 weeks ended

July 31, July 26, July 31, July 26,

2008 2007 2008 2007

Thousands Except Per Share Amounts

Revenues:

Retail drug store sales $1,201,468 $1,195,591 $2,421,113 $2,380,602

Pharmacy benefit

services revenues 131,269 78,958 318,605 190,957

Total revenues 1,332,737 1,274,549 2,739,718 2,571,559

Costs and expenses:

Cost of retail drug

store sales 881,268 881,118 1,775,745 1,762,177

Prescription drug plan

benefit costs 96,500 54,174 259,589 146,670

Operating and administrative

expenses 307,388 295,030 617,049 581,300

Legal settlements and

other disputes, net 500 (431) 500 (431)

Provision for store

closures and asset

impairments, net 599 371 816 9,586

Operating income 46,482 44,287 86,019 72,257

Interest expense 2,786 1,772 5,572 3,448

Interest income (178) (282) (433) (478)

Income from continuing

operations before income

taxes 43,874 42,797 80,880 69,287

Income taxes 16,377 17,059 30,300 27,523

Income from continuing

operations 27,497 25,738 50,580 41,764

Income (loss) from

discontinued operations,

net of tax - 869 456 (2,119)

Net income $27,497 $26,607 $51,036 $39,645

Earnings per common share:

Basic:

Income from continuing

operations $0.78 $0.69 $1.42 $1.11

Income (loss) from

discontinued operations - 0.02 0.02 (0.05)

Net income 0.78 0.71 1.44 1.06

Diluted:

Income from continuing

operations $0.76 $0.67 $1.40 $1.09

Income (loss) from

discontinued operations - 0.02 0.01 (0.06)

Net income 0.76 0.69 1.41 1.03

Dividends per common share $0.14 $0.14 $0.28 $0.28

Weighted average number of

shares outstanding:

Basic 35,350 37,417 35,553 37,469

Diluted 36,062 38,326 36,252 38,412

Number of stores in

continuing operations,

beginning of period 516 487 510 486

Stores opened 4 2 6 3

Stores acquired 2 6 7 12

Stores closed (1) (3) (2) (9)

Number of stores in

continuing operations,

end of period 521 492 521 492

Number of stores in

discontinued operations,

beginning of period - 13 - 23

Stores opened - - - -

Stores acquired - - - -

Stores closed - (13) - (23)

Number of stores in

discontinued operations,

end of period - - - -

Store relocations - - - 1

Condensed Consolidated Balance Sheets (unaudited)

July 31, January 31, July 26,

2008 2008 2007

Thousands Except Share Information

Assets

Current Assets:

Cash and cash equivalents $26,867 $27,019 $24,463

Accounts receivable, net 433,828 334,972 301,157

Merchandise inventories, net 465,981 510,482 494,473

Deferred income taxes 62,611 64,500 59,985

Prepaid expenses and other current

assets 23,823 22,043 23,280

Assets held for sale 4,173 4,173 4,177

Total current assets 1,017,283 963,189 907,535

Property:

Land 119,312 116,564 113,279

Buildings and leasehold improvements 755,504 725,930 692,893

Equipment and fixtures 645,383 628,556 612,429

Total 1,520,199 1,471,050 1,418,601

Less accumulated depreciation 752,940 715,682 704,086

Property, net 767,259 755,368 714,515

Goodwill 84,394 84,394 84,450

Intangible assets, net 32,350 32,240 25,775

Other non-current assets 11,419 11,525 5,340

Total $1,912,705 $1,846,716 $1,737,615

Liabilities and Stockholders' Equity

Current Liabilities:

Trade accounts payable $261,973 $273,953 $270,740

Pharmacy benefits payable 254,273 176,829 123,475

Accrued employee compensation and

benefits 104,350 120,458 120,118

Taxes payable 31,604 58,998 54,383

Other accrued expenses 64,426 63,110 66,769

Current maturities of debt 36,727 36,727 6,727

Total current liabilities 753,353 730,075 642,212

Long-term debt 205,636 183,364 123,364

Deferred income taxes and other

long-term liabilities 100,228 105,352 120,229

Total liabilities 1,059,217 1,018,791 885,805

Commitments and Contingencie
'/>"/>

SOURCE Longs Drug Stores Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Longs Drug Stores Corporation Declares Cash Dividend on Common Shares
2. Longs Reports Preliminary June Retail Drug Store Sales
3. Longs Drug Stores to Continue to Service Medi-Cal Patients
4. Radiation therapy prolongs life in men with recurrent prostate cancer
5. Longs Reports Preliminary May Retail Drug Store Sales
6. Golf prolongs life
7. Longs Drug Stores Corporation Announced at Its Annual Meeting of Stockholders
8. Longs Drug Stores Donates Supplies to Victims of Santa Cruz Mountain Fires
9. Longs Drugs Partners With Google on the Launch of Google Health
10. Longs Reports Preliminary March Retail Drug Store Sales
11. Longs Drug Stores Announces Todd Vasos Executive Vice President and Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
(Date:6/24/2016)... ... 2016 , ... National recruitment firm Slone Partners is pleased to ... genomics experience, as Vice President of North American Capital Sales at HTG Molecular ... the sales team in the commercialization of the HTG EdgeSeq system and associated reagents ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
Breaking Medicine Technology: